$310,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Telehealth Compounded medicines Quality and safety manufacturing"
You can find more data on corporate lobbying on Quiver Quantitative.
HIMS Insider Trading Activity
HIMS insiders have traded $HIMS stock on the open market 118 times in the past 6 months. Of those trades, 0 have been purchases and 118 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 45 sales selling 1,214,168 shares for an estimated $55,660,901.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 25 sales selling 303,064 shares for an estimated $11,008,819.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 15 sales selling 138,873 shares for an estimated $5,862,603.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 10 sales selling 79,528 shares for an estimated $3,835,936.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 15 sales selling 99,188 shares for an estimated $3,674,554.
- IRENE BECKLUND (PAO) has made 0 purchases and 7 sales selling 32,088 shares for an estimated $1,411,579.
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,287 shares for an estimated $798,976
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HIMS Hedge Fund Activity
We have seen 256 institutional investors add shares of HIMS stock to their portfolio, and 219 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 5,862,886 shares (-19.5%) from their portfolio in Q1 2025, for an estimated $173,248,281
- D. E. SHAW & CO., INC. added 5,390,213 shares (+841.7%) to their portfolio in Q1 2025, for an estimated $159,280,794
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 4,332,982 shares (-68.7%) from their portfolio in Q1 2025, for an estimated $128,039,618
- SRS INVESTMENT MANAGEMENT, LLC added 4,000,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $118,200,000
- ICONIQ CAPITAL, LLC removed 2,874,769 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $84,949,423
- GOLDMAN SACHS GROUP INC added 2,738,501 shares (+49.4%) to their portfolio in Q1 2025, for an estimated $80,922,704
- WELLINGTON MANAGEMENT GROUP LLP removed 2,569,041 shares (-75.1%) from their portfolio in Q1 2025, for an estimated $75,915,161
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HIMS Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 06/04/2025
- Citigroup issued a "Sell" rating on 05/06/2025
- B of A Securities issued a "Underperform" rating on 04/29/2025
- Canaccord Genuity issued a "Buy" rating on 02/19/2025
To track analyst ratings and price targets for HIMS, check out Quiver Quantitative's $HIMS forecast page.
HIMS Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 9 analysts offer price targets for $HIMS in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Jailendra Singh from Truist Securities set a target price of $48.0 on 07/17/2025
- Craig Hettenbach from Morgan Stanley set a target price of $40.0 on 06/11/2025
- Ryan MacDonald from Needham set a target price of $65.0 on 06/04/2025
- Korinne Wolfmeyer from Piper Sandler set a target price of $39.0 on 05/06/2025
- Daniel Grosslight from Citigroup set a target price of $30.0 on 05/06/2025
- Allen Lutz from B of A Securities set a target price of $26.0 on 04/29/2025
- Jonna Kim from TD Cowen set a target price of $30.0 on 04/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
